Preview

Lechaschi Vrach

Advanced search

Elevation of transaminases. What if not the liver?

https://doi.org/10.51793/OS.2024.27.3.011

Abstract

Background. According to Russian studies, the average age of Duchenne muscular dystrophy diagnosis is 7-8 years. This is because, on one hand, Duchenne muscular dystrophy is a rare disease, and a doctor may never see it throughout their clinical practice. On the other hand, the clinical picture of the disease is diverse and does not have pronounced symptoms in the early stages of development. Doctors often make mistakes in diagnosis by considering the consequences of the disease or focusing on one manifestation without seeing the entire complex of symptoms and its root cause. For example, one of the manifestations of the disease is elevated liver enzymes: transaminases (ALT, AST) and LDH. About 50% of misdiagnoses in Duchenne muscular dystrophy are related to liver damage. These children may be observed for years by infectious disease specialists or pediatric gastroenterologists with unspecified diagnoses, undergoing new and sometimes invasive tests.

Conclusion. Currently, many patients with Duchenne muscular dystrophy have access to pathogenetic therapy. Unfortunately, it does not restore lost functions but can preserve existing ones and clinically convert the aggressive form of Duchenne muscular dystrophy into a milder Becker form. This is why it is crucial to inform primary care pediatricians, pediatric gastroenterologists, and infectious disease specialists about the mechanisms of non-hepatic transaminase elevation and diagnostic algorithms for muscular dystrophies.

About the Author

I. V. Sharkova
Federal State Budgetary Scientific Institution Research Center named after Academician N. P. Bochkov of the Ministry of Science and Higher Education of the Russian Federation
Россия

Inna V. Sharkova, Dr. of Sci. (Med.), Neurologist, Leading researcher of the scientific advisory

1 Moskvorechye str., Moscow, 115522 



References

1. Zinina E. V., Bulakh M. V., Ryzhkova O. P., Shchagina O. A., Polyakov A. V. Change in the spectrum of detected mutations in the DMD gene depending on the methodological capabilities of the laboratory. Nervno-myshechnye bolezni. 2023; 13 (1): 33-43. (In Russ.)

2. Clinical recommendations. Progressive Duchenne muscular dystrophy. Becker's progressive muscular dystrophy. MoH. 2023. (In Russ.)

3. Shin’ichi Takedaa, Clemensb P. R., Hoffman E. P. Exon-Skipping in Duchenne Muscular Dystrophy. Journal of Neuromuscular Diseases. 2021; 8: S343-S358.

4. Ciafaloni E., Fox D. J., Pandya S., et al. Delayed diagnosis in Duchenne muscular dystrophy: data from the Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STARnet). J Pediatr. 2009; 155: 380-385.

5. Gremyakova O. I. The "invisible" boys. Redkie bolezni v Rossii. 2021; 19. (In Russ.)

6. Korones D. N., Brown M. R., Palis J. Liver Function Tests Are Not Always Tests of Liver Function. American. Journal of Hematology. 2001; 66: 46-48.

7. Wright M. A., Yang M. L., et al. Consider Muscle Disease in Children with Elevated Transaminase. JABFM. 2012; 4 (25).

8. McMillan H. J., Gregas M., Darras B. T., Kang P. B. Serum transaminase levels in boys with Duchenne and Becker muscular dystrophy. Pediatrics. 2011; 127: e132-136.

9. Vajro P., Maddaluno S., Veropalumbo C. Persistent hypertransaminasemia in asymptomatic children: a stepwise approach. World J Gastroenterol. 2013; 19: 2740-2751.

10. Pearson C. M., Chowdhury S. R., Fowler W. M. Jr., et al. Studies of enzymes in serum in muscular dystrophy. II. Diagnostic and prognostic significance in relatives of dystrophic persons. Pediatrics. 1961; 28: 962-970.

11. Thomson W. H. Serum enzyme studies in acquired disease of skeletal muscle. Clin Chim Acta. 1971; 35: 193-199.

12. Website. Scientific diagnostic programs (med-gen.ru) https://med-gen.ru/spetcialistam/nauchnye-diagnosticheskie-programmy/. (In Russ.) Acessed: 21.02.2024.

13. Yakovlev I. A., Deev R. V., Solovyеva V. V., et al. Pre- and posttranscriptional genetic information modification in muscular dystrophy treatment. Geny & kletki. 2016; 2 (XI). (In Russ.)


Review

For citations:


Sharkova I.V. Elevation of transaminases. What if not the liver? Lechaschi Vrach. 2024;(3):67-70. (In Russ.) https://doi.org/10.51793/OS.2024.27.3.011

Views: 144

JATS XML

ISSN 1560-5175 (Print)
ISSN 2687-1181 (Online)